DGIdb - CERIVASTATIN Drug Record

CERIVASTATIN chembl:CHEMBL1477

Alternate Names:

BAYCOL
CERIVASTATIN
LIPOBAY
LIPOBAY®
CERIVASTATIN ACID
(3R,5S,6E)-7-(4-(4-FLUOROPHENYL)-5-(METHOXYMETHYL)-2,6-BIS(1-METHYLETHYL)-3-PYRIDINYL)-3,5-DIHYDROXY-6-HEPTENOIC ACID
(3R,5S,6E)-7-(4-(P-FLUOROPHENYL)-2,6-DIISOPROPYL-5-(METHOXYMETHYL)-3-PYRIDYL)-3,5-DIHYDROXY-6-HEPTENOIC ACID
BAYCOL®
pubchem.compound:446156
chembl:CHEMBL1477
rxcui:596723
chemidplus:145599-86-6
drugbank:00439

Drug Info:

(0 More Sources)

Publications:

Kameyama Y et al., 2005, Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B15, SLCO1B115 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells., Pharmacogenet Genomics
Marciante KD et al., 2011, Cerivastatin, genetic variants, and the risk of rhabdomyolysis., Pharmacogenet Genomics
Shiomi et al., 1999, Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits., Br. J. Pharmacol.
Blumenthal, 2000, Statins: effective antiatherosclerotic therapy., Am. Heart J.
Denoyelle et al., 2001, Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study., Carcinogenesis
Wong et al., 2001, Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin., Clin. Cancer Res.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Ganné et al., 2000, Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes--a possible protective mechanism against atherothrombosis., Thromb. Haemost.
Staffa JA et al., 2002, Cerivastatin and reports of fatal rhabdomyolysis., N Engl J Med
Ishikawa C et al., 2004, A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin., J Hum Genet

CERIVASTATIN HMGCR

Interaction Score: 6.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction Inhibition of HMG-CoA reductase

Specific Action of the Ligand Competitive

Endogenous Drug? False

PMIDs:
10193776 10740137 11470741 11448925 11752352 11057870

Sources:
GuideToPharmacology TTD
CERIVASTATIN RYR2

Interaction Score: 3.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21386754

Sources:
PharmGKB
CERIVASTATIN CYP2C8

Interaction Score: 1.77

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11844864 15365880

Sources:
PharmGKB
CERIVASTATIN SLCO1B1

Interaction Score: 0.6

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15970799

Sources:
PharmGKB

PharmGKB: cerivastatin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Kameyama Y et al., 2005, Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B15, SLCO1B115 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells., Pharmacogenet Genomics

Marciante KD et al., 2011, Cerivastatin, genetic variants, and the risk of rhabdomyolysis., Pharmacogenet Genomics

Ishikawa C et al., 2004, A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin., J Hum Genet

GuideToPharmacology: 135650063
- Version: 29-September-2020
Alternate Names:

CERIVASTATIN GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Cerivastatin
- Version: 2020.06.01
Alternate Names:

D03KIA TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1477
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Details of the Assay for Interaction	Inhibition of HMG-CoA reductase
Specific Action of the Ligand	Competitive
Endogenous Drug?	False

CERIVASTATIN Drug Record

CERIVASTATIN chembl:CHEMBL1477

Alternate Names:

Drug Info:

Publications:

CERIVASTATIN HMGCR

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Details of the Assay for Interaction Inhibition of HMG-CoA reductase Specific Action of the Ligand Competitive Endogenous Drug? False

PMIDs: 10193776 10740137 11470741 11448925 11752352 11057870

Sources: GuideToPharmacology TTD

CERIVASTATIN RYR2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21386754

Sources: PharmGKB

CERIVASTATIN CYP2C8

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11844864 15365880

Sources: PharmGKB

CERIVASTATIN SLCO1B1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15970799

Sources: PharmGKB

PharmGKB: cerivastatin

Alternate Names:

Drug Info:

GuideToPharmacology: 135650063

Alternate Names: CERIVASTATIN GuideToPharmacology Ligand Name

Drug Info:

Publications:

TTD: Cerivastatin

Alternate Names: D03KIA TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1477

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction Inhibition of HMG-CoA reductase

Specific Action of the Ligand Competitive

Endogenous Drug? False

PMIDs:
10193776 10740137 11470741 11448925 11752352 11057870

Sources:
GuideToPharmacology TTD

Interaction Types & Directionality:

n/a

PMIDs:
21386754

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11844864 15365880

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15970799

Sources:
PharmGKB

Alternate Names:

CERIVASTATIN GuideToPharmacology Ligand Name

Alternate Names:

D03KIA TTD Drug ID